RG7795

From WikiMD's Food, Medicine & Wellness Encyclopedia



RG7795 (previously ANA773) is an antiviral drug candidate that as of 2015 had been in Phase II trials in hepatitis B.[1] It is an orally-available prodrug of isatoribine,[2] that was under development by Anadys Pharmaceuticals when it was acquired by Roche in 2011.[3] Its active metabolite is an [agonist]] of TLR7; activation of TLR7 causes secretion of endogenous type 1 interferons, which have antiviral activity.[2]

References[edit | edit source]

  1. ↑ "RG 7795". AdisInsight. Retrieved 28 August 2017.
  2. ↑ 2.0 2.1
  3. ↑
Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Retrieved from "https://wikimd.com/w/index.php?title=RG7795&oldid=5279231"

Contributors: Prab R. Tumpati, MD